Advertisement
Organisation › Details
Merck (DE) (Group)
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 51,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene- editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – Merck is everywhere. In 2017, Merck generated sales of €15.3 billion in 66 countries. Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the business sectors operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. *
Start | 1668-01-01 established_pre | |
Industry | pharmaceutical | |
Industry 2 | reagents (bio/biochemical) | |
Person | Garijo, Belén (Merck (DE) 202007– promoted Deputy CEO before CEO of Merck Serono before COO before Sanofi) | |
Person 2 | von Roeder, Helene (Merck (DE) 202403 CFO) | |
Region | Darmstadt | |
Country | Germany | |
Street | 250 Frankfurter Str. | |
City | 64293 Darmstadt | |
Tel | +49-6151-72-0 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | I: 50,001 to 100,0 (2023-12-31) |
Currency | EUR | |
Annual sales | 20,993,000,000 (sales, net, consolidated (2023) 2023-12-31) | |
Profit | 2,834,000,000 (2023-12-31) | |
Cash | 1,982,000,000 (2023-12-31) | |
* Document for »About Section«: Merck KGaA. (3/4/19). "Press Release: Merck Awarded Canadian CRISPR Nickase Patent for Foundational Genome-Editing Technology". Darmstadt. | ||
Record changed: 2024-06-12 |
Advertisement
More documents for Merck (DE) (Group)
- [1] Enara Bio Ltd.. (10/3/24). "Press Release: Enara Bio Raises $32.5 Million Series B Financing to Advance First-in-Class Pipeline of TCR-based Immunotherapies Targeting Novel Dark Antigens". Oxford....
- [2] Merck KGaA. (6/24/24). "Press Release: Merck Provides Update on Xevinapant Program in Locally Advanced Head and Neck Cancer [ Not intended for UK-, US- or Canada-based media ]". Darmstadt....
- [3] Merck KGaA. (5/29/24). "Press Release: Merck Signs MoU with KAIST to Advance Scientific Collaboration". Darmstadt....
- [4] Merck KGaA. (5/22/24). "Press Release: Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 Million". Darmstadt....
- [5] Merck KGaA. (4/25/24). "Press Release: Merck Invests More Than € 300 Million in New Life Science Research Center in Germany". Darmstadt....
- [6] Outrun Therapeutics Ltd.. (4/18/24). "Press Release: Outrun Therapeutics Launches with a $10m Seed Financing from M Ventures and MP Healthcare Venture Management to Develop a Protein Stabilisation Pipeline". Dundee....
- [7] C4 Therapeutics, Inc.. (3/4/24). "Press Release: C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins". Watertown, MA....
- [8] Precirix N.V.. (2/29/24). "Press Release: Tom Plitz Commences Role as Chief Executive Officer of Precirix". Brussels....
- [9] Merck KGaA. (1/4/24). "Press Release: Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [10] Merck KGaA. (12/4/23). "Press Release: Merck Strengthens Oncology Portfolio through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib [Not intended for UK-, US- or Canada-based media]". Darmstadt....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top